Efficacy Study of Recombinant Protein (Ecallantide) to Reduce Blood Loss During Primary Coronary Bypass Grafting or Valve Repair/Replacement

Inclusion Criteria: * Men and women ≥18 to ≤85 years of age * Elective primary coronary artery bypass grafting (CABG), single valve repair, or single valve replacement requiring CPB and full sternotomy * No plan to use desmopressin acetate (DDAVP), atrial natriuretic hormone, E-aminocaproic acid (EACA), tranexamic acid, or aprotinin during or postoperatively * Female participants must be non-lactating and not pregnant * If of childbearing potential, female participants must agree to use adequate contraception for 1 month after receiving study drug Exclusion Criteria: * Concomitant surgery including but not limited to atrial septal defect repair, multiple valve replacement, carotid endarterectomy, and combined CABG and valve procedure * Planned hypothermic CPB using temperatures less than 28 degrees Celsius * Weight \<55 kilograms (kg) * Major end organ dysfunction, defined as: * Cardiac: * Left ventricular ejection fraction (LVEF) \< 30% by left ventriculography, echocardiogram, or catheterization (within 90 days prior to screening) * Use of positive IV inotropic agents within 12 hours prior to surgery * Preoperative use of intra-aortic balloon pump (IABP), left ventricular assist device (LVAD), or extracorporeal membrane oxygenation (ECMO) * Renal: Serum creatinine \> 1.5 milligrams per deciliter (mg/dL) * Hepatic: Aspartate aminotransferase (AST) or alanine transferase (ALT) \> 2.5 x upper limit normal * Hematologic: * Preoperative hematocrit (Hct) \< 30% * Platelet count \< 100,000/mm\^3 * Planned transfusion during surgical procedure * History or family history of bleeding or clotting disorder (for example, von Willebrand's Disease, idiopathic thrombocytopenia purpura (ITP), thrombotic thrombocytopenia purpura (TTP), hematologic malignancy) * Prothrombin time (PT) or activated partial thromboplastin time * (aPTT) \> 1.5 x normal range; if receiving unfractionated heparin preoperatively, then abnormal preoperative PT/aPTT permitted * Serious intercurrent illness or active infection * Previous exposure to ecallantide * Known allergy to ecallantide or any of its components, fentanyl, midazolam, isoflurane, propofol, morphine, heparin, or protamine * Autologous blood donation ≤ 30 days month prior to surgery * Known substance abuse within 6 months prior to surgery * Receipt of an investigational drug or device within 30 days prior to participation in the current study * Administration of: * Eptifibatide \< 12 hours prior to surgery * Tirofiban hydrochloride (HCl) \< 12 hours prior to surgery * Enoxaparin sodium or other low- molecular-weight heparin \< 24 hours prior to surgery * Clopidogrel \<5 days prior to surgery * Warfarin \<5 days prior to surgery (Warfarin must be discontinued 5 days prior to surgery and PT must be \< 18 seconds) * Ticlopidine \<7 days prior to surgery * Abciximab \<24 hours prior to surgery